Skip to main content
Premium Trial:

Request an Annual Quote

LineaGen's MS, Autism Diagnostics Project Using Affy Arrays

NEW YORK (GenomeWeb News) – Researchers at the University of Utah and Vanderbilt University are using Affymetrix’s genotyping arrays along with LineaGen’s biomarker diagnostics technology to hunt for genetic markers that could be used in the treatment and diagnosis of multiple sclerosis and autism, Affymetrix and LineaGen jointly announced today.
 
In a project funded and managed by Salt Lake City-based LineaGen, the scientists are using Affy’s Genome-Wide Human SNP Array 6.0 to analyze data from the Utah Population Database to compare genetic information with “decades’ worth of longitudinal clinical data,” the firms said.
 
The researchers expect the study will lead to enhanced understanding of these two diseases, more effective use of existing treatments, and the development of molecular diagnostics and therapies.
 
The Affy arrays will be run at the Vanderbilt Microarray Shared Resource at Vanderbilt University Medical Center.
 
“We have a valuable and unique genetic population resource at the University of Utah and now we can cost-effectively conduct larger-scale studies to determine the genetic associations of common diseases like MS and autism," Mark Leppert, co-chair of the University of Utah’s department of human genetics, said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more